BioNano Genomics, Inc. (BNGO)
| Market Cap | 2.64B |
| Revenue (ttm) | 7.30M |
| Net Income (ttm) | -37.28M |
| Shares Out | 132.94M |
| EPS (ttm) | -0.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $9.73 |
| Previous Close | $10.02 |
| Change ($) | -0.29 |
| Change (%) | -2.89% |
| Day's Open | 10.08 |
| Day's Range | 9.38 - 10.71 |
| Day's Volume | 26,459,776 |
| 52-Week Range | 0.25 - 15.69 |
BNGO Stock has alot of potential for growth in the long term but its risks currently limit its attractiveness as an investment The post Investors Should Have BNGO Stock on Their Long-Term Watc...
BNGO stock is on the move today without any real company news. Here's what you should know about Bionano Genomics now.
Let's take a look at two companies that Wood has her eye on and has recently added to Ark's large portfolio of funds.
BNGO stock is an investment in the future of gene discovery and therapy as Bionano pushes the boundaries of optical genome mapping tech. The post Leverage the Power of Genetics Tech With Biona...
Bionano (BNGO) will provide updates on its revenues and earnings when it reports fourth-quarter and full-year 2020 results.
Proprietary scoring algorithm may help identify novel genes for nervous system disorders; applications include patient testing and eventually discovery research with Saphyr Proprietary scoring...
Bionano Genomics makes Saphyr, a genome imaging tool. With BNGO stock doubling over the past month, investors should give the company a look.
The genetic testing specialist could access a major new market.
The Alternative Harvest ETF, CIIC Merger, Newell Brands and Bionano Genomics were our top stock trades for Tuesday. Let's look at the charts.
BNGO stock has continued to shoot higher today on a string of good news that has investors excited about this company's long-term prospects. The post BNGO Stock: Why Bionano Genomics Shares Ra...
BNGO stock is up 280% this year as its story begins to unfold. The stock may cool off, but it looks like there are many chapters to come for the firm.
SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the BTIG MedTech, Digital Health, Life Scie...
Among all the biotech pivots toward the novel coronavirus, BNGO stock represents one of the most sensible. But does that mean shares are a buy?
Bionano Genomics, Inc. (BNGO) closed at $11.80 in the latest trading session, marking a +1.29% move from the prior day.
A dazzling BNGO stock has flown under the radar in 2021, but don't expect shares of this newly-minted mid-cap to remain a secret. The post The Sequence to More Highs is Unfolding in BNGO Stock...
BioNano has a promising clinical platform. It needs to generate more revenues before BNGO stock will be worth its current price, however.
SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that its Saphyr system is being piloted by the University Health Network's (UHN) Laboratory ...
These high-flying stocks have been moneymakers since early November.
SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that presentation recordings from its 5-day Next-Generation Cytogenomics Symposium, which took plac...
Bionano Genomics, Inc. (BNGO) closed at $11.85 in the latest trading session, marking a -1.41% move from the prior day.
Bionano Genomics takes advantage of a spike to sell shares at highs. Cash likely represents about 19% of the BNGO stock market capitalization as a result of two capital raises.
Mustang Bio (NASDAQ: MBIO) shares are trading higher after the company announced the FDA has lifted the clinical hold for its pivotal phase 2 MB-107 clinical trial. The company plans to enroll...
SAN DIEGO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced a presentation by the Director of the Clinical Cytogenomics Laboratory of Children's Hospital Los A...
This high-flying stock is already one of the biggest winners in the new year.
Addition of Microsoft Azure as a High-Performance Computing provider reduces compute cost for genetic disease analysis by more than 50%, compute time by 30% Addition of Microsoft Azure as a Hi...
These popular companies have rallied between 1,000% and 2,400% since late July.
Analysts are growing more bullish on the genetic testing specialist's growth potential.
SAN DIEGO, Jan. 25, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the closing of its previously announced underwritten public offering of 38,333,352 shares of...
A Wall Street analyst's target-price hike may have had something to do with it.
Bionano's products facilitate research into many diseases and the development of new treatments. Investors should buy BNGO stock.
UPDATE: Bionano Genomics prices $200 million underwritten stock offering at a discount of $6 a share
Bionano Genomics Inc. priced a $200 million underwritten stock offering announced late Tuesday at a discount of $6 a share, selling 33.3 million shares. The stock closed Tuesday at an alltime ...
SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the pricing of its previously announced underwritten public offering of 33,333,350 shares of...
The genome testing company's investors endured a volatile day.
Bionano Genomics Inc. on Tuesday announced its second share sale in less than a month amid an unexplained spike in its price and volume, sending shares down in after-hours trading. Bionano did...
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that it plans to offer and sell, subject to market and other conditions, shares of its commo...
BNGO stock is on the move as an up-and-coming biotech firm leverages the power of optical genome mapping technology. The post Map a Course for Breakthrough Science With BioNano Genomics appear...
SAN DIEGO, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the last day of its five-day Next-Generation Cytogenomics Symposium featured presentations by ...
Positive reviews from doctors have investors excited about the genome testing company's growth prospects.
SAN DIEGO, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that day four of its five-day Next-Generation Cytogenomics Symposium featured seven Saphyr users pr...
The genome analysis specialist could help bring about better healthcare outcomes for people with cancer.
SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that day three of its five-day Next-Generation Cytogenomics Symposium featured six Saphyr users pre...
SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Com...
SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that day two of its five-day Next-Generation Cytogenomics Symposium featured eight Saphyr users pre...
SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the closing of its previously announced underwritten public offering of 33,368,851 shares of...
The genetic testing specialist is revealing new insights that could help explain why the coronavirus affects people differently.
About BNGO
Bionano Genomics operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's B... [Read more...]
| Industry Diagnostics & Research | IPO Date Aug 21, 2018 |
| CEO R. Erik Holmlin | Employees 97 |
| Stock Exchange NASDAQ | Ticker Symbol BNGO |
Financial Performance
In 2019, BNGO's revenue was $10.13 million, a decrease of -15.59% compared to the previous year's $12.00 million. Losses were -$29.82 million, 61.2% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for BNGO stock is "Buy." The 12-month stock price forecast is 10.94, which is an increase of 12.44% from the latest price.